221 related articles for article (PubMed ID: 28337317)
1. Structural Requirements of HDAC Inhibitors: SAHA Analogues Modified at the C2 Position Display HDAC6/8 Selectivity.
Negmeldin AT; Padige G; Bieliauskas AV; Pflum MK
ACS Med Chem Lett; 2017 Mar; 8(3):281-286. PubMed ID: 28337317
[TBL] [Abstract][Full Text] [Related]
2. The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
Negmeldin AT; Knoff JR; Pflum MKH
Eur J Med Chem; 2018 Jan; 143():1790-1806. PubMed ID: 29150330
[TBL] [Abstract][Full Text] [Related]
3. The structural requirements of histone deacetylase inhibitors: SAHA analogs modified at the C5 position display dual HDAC6/8 selectivity.
Negmeldin AT; Pflum MKH
Bioorg Med Chem Lett; 2017 Aug; 27(15):3254-3258. PubMed ID: 28648461
[TBL] [Abstract][Full Text] [Related]
4. Structural Requirements of Histone Deacetylase Inhibitors: SAHA Analogs Modified on the Hydroxamic Acid.
Bieliauskas AV; Weerasinghe SV; Negmeldin AT; Pflum MK
Arch Pharm (Weinheim); 2016 May; 349(5):373-82. PubMed ID: 27062198
[TBL] [Abstract][Full Text] [Related]
5. The structural requirements of histone deacetylase inhibitors: Suberoylanilide hydroxamic acid analogs modified at the C3 position display isoform selectivity.
Choi SE; Weerasinghe SV; Pflum MK
Bioorg Med Chem Lett; 2011 Oct; 21(20):6139-42. PubMed ID: 21889343
[TBL] [Abstract][Full Text] [Related]
6. Discovery of meta-sulfamoyl N-hydroxybenzamides as HDAC8 selective inhibitors.
Zhao C; Zang J; Ding Q; Inks ES; Xu W; Chou CJ; Zhang Y
Eur J Med Chem; 2018 Apr; 150():282-291. PubMed ID: 29533873
[TBL] [Abstract][Full Text] [Related]
7. Synthesis, bioevaluation and docking study of 5-substitutedphenyl-1,3,4-thiadiazole-based hydroxamic acids as histone deacetylase inhibitors and antitumor agents.
Nam NH; Huong TL; Dung do TM; Dung PT; Oanh DT; Park SH; Kim K; Han BW; Yun J; Kang JS; Kim Y; Han SB
J Enzyme Inhib Med Chem; 2014 Oct; 29(5):611-8. PubMed ID: 24020585
[TBL] [Abstract][Full Text] [Related]
8. Development of a Bestatin-SAHA Hybrid with Dual Inhibitory Activity against APN and HDAC.
Cao J; Zhao W; Zhao C; Liu Q; Li S; Zhang G; Chou CJ; Zhang Y
Molecules; 2020 Oct; 25(21):. PubMed ID: 33126591
[TBL] [Abstract][Full Text] [Related]
9. Structure of 'linkerless' hydroxamic acid inhibitor-HDAC8 complex confirms the formation of an isoform-specific subpocket.
Tabackman AA; Frankson R; Marsan ES; Perry K; Cole KE
J Struct Biol; 2016 Sep; 195(3):373-378. PubMed ID: 27374062
[TBL] [Abstract][Full Text] [Related]
10. Novel Hydroxamic Acids Incorporating 1-((1H-1,2,3-Triazol-4-yl)methyl)- 3-substituted-2-oxoindolines: Synthesis, Biological Evaluation and SAR Analysis.
Dung DTM; Huan NV; Cam DM; Hieu DC; Hai PT; Huong LT; Kim J; Choi JE; Kang JS; Han SB; Nam NH
Med Chem; 2018; 14(8):831-850. PubMed ID: 29807520
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and biological evaluation of dual HDAC and VEGFR inhibitors as multitargeted anticancer agents.
Xue X; Zhang Y; Liao Y; Sun D; Li L; Liu Y; Wang Y; Jiang W; Zhang J; Luan Y; Zhao X
Invest New Drugs; 2022 Feb; 40(1):10-20. PubMed ID: 34463890
[TBL] [Abstract][Full Text] [Related]
12. Design and synthesis of novel and highly-active pan-histone deacetylase (pan-HDAC) inhibitors.
Tashima T; Murata H; Kodama H
Bioorg Med Chem; 2014 Jul; 22(14):3720-31. PubMed ID: 24864038
[TBL] [Abstract][Full Text] [Related]
13. Structural biasing elements for in-cell histone deacetylase paralog selectivity.
Wong JC; Hong R; Schreiber SL
J Am Chem Soc; 2003 May; 125(19):5586-7. PubMed ID: 12733869
[TBL] [Abstract][Full Text] [Related]
14. Histone deacetylase inhibitor suberoylanilide hydroxamic acid alleviates liver fibrosis by suppressing the transforming growth factor-β1 signal pathway.
Wang Y; Zhao L; Jiao FZ; Zhang WB; Chen Q; Gong ZJ
Hepatobiliary Pancreat Dis Int; 2018 Oct; 17(5):423-429. PubMed ID: 30249543
[TBL] [Abstract][Full Text] [Related]
15. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors.
Khan N; Jeffers M; Kumar S; Hackett C; Boldog F; Khramtsov N; Qian X; Mills E; Berghs SC; Carey N; Finn PW; Collins LS; Tumber A; Ritchie JW; Jensen PB; Lichenstein HS; Sehested M
Biochem J; 2008 Jan; 409(2):581-9. PubMed ID: 17868033
[TBL] [Abstract][Full Text] [Related]
16. The histone deacetylase inhibitors suberoylanilide hydroxamic (Vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells.
Fedier A; Dedes KJ; Imesch P; Von Bueren AO; Fink D
Int J Oncol; 2007 Sep; 31(3):633-41. PubMed ID: 17671692
[TBL] [Abstract][Full Text] [Related]
17. Improved Anticancer Activities of a New Pentafluorothio-Substituted Vorinostat-Type Histone Deacetylase Inhibitor.
Goehringer N; Peng Y; Nitzsche B; Biermann H; Pradhan R; Schobert R; Herling M; Höpfner M; Biersack B
Pharmaceuticals (Basel); 2021 Dec; 14(12):. PubMed ID: 34959719
[TBL] [Abstract][Full Text] [Related]
18. Antitumor effects of a novel phenylbutyrate-based histone deacetylase inhibitor, (S)-HDAC-42, in prostate cancer.
Kulp SK; Chen CS; Wang DS; Chen CY; Chen CS
Clin Cancer Res; 2006 Sep; 12(17):5199-206. PubMed ID: 16951239
[TBL] [Abstract][Full Text] [Related]
19. Synthesis of N-hydroxycinnamides capped with a naturally occurring moiety as inhibitors of histone deacetylase.
Huang WJ; Chen CC; Chao SW; Lee SS; Hsu FL; Lu YL; Hung MF; Chang CI
ChemMedChem; 2010 Apr; 5(4):598-607. PubMed ID: 20209563
[TBL] [Abstract][Full Text] [Related]
20. Design, Synthesis and Biological Evaluation of Novel N-hydroxyheptanamides Incorporating 6-hydroxy-2-methylquinazolin-4(3H)-ones as Histone Deacetylase Inhibitors and Cytotoxic Agents.
Minh NV; Thanh NT; Lien HT; Anh DTP; Cuong HD; Nam NH; Hai PT; Minh-Ngoc L; Le-Thi-Thu H; Chinh LV; Vu TK
Anticancer Agents Med Chem; 2019; 19(12):1543-1557. PubMed ID: 31267876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
